April 25, 2023 07:37 AM EDT

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Amber Tong

Novartis’ decision to buy a radioligand therapy from Clovis is proving a boon for 3B Pharmaceuticals, the small German biotech that originally developed the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Amber Tong

Sign up to read this article for free.

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

No­var­tis pays Ger­man biotech $40M for ra­di­oli­gand ther­a­py, di­ag­nos­tic hit­ting 'first-in-class' tar­get

Amber Tong

Sign up to read this article for free.

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?